These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
132 related articles for article (PubMed ID: 34961705)
21. Safety and microbiological activity of phage therapy in persons with cystic fibrosis colonized with Pseudomonas aeruginosa: study protocol for a phase 1b/2, multicenter, randomized, double-blind, placebo-controlled trial. Tamma PD; Souli M; Billard M; Campbell J; Conrad D; Ellison DW; Evans B; Evans SR; Greenwood-Quaintance KE; Filippov AA; Geres HS; Hamasaki T; Komarow L; Nikolich MP; Lodise TP; Nayak SU; Norice-Tra C; Patel R; Pride D; Russell J; Van Tyne D; Chambers HF; FowlerJr VG; Schooley RT; Trials; 2022 Dec; 23(1):1057. PubMed ID: 36578069 [TBL] [Abstract][Full Text] [Related]
22. Effect of azithromycin on pulmonary function in patients with cystic fibrosis uninfected with Pseudomonas aeruginosa: a randomized controlled trial. Saiman L; Anstead M; Mayer-Hamblett N; Lands LC; Kloster M; Hocevar-Trnka J; Goss CH; Rose LM; Burns JL; Marshall BC; Ratjen F; JAMA; 2010 May; 303(17):1707-15. PubMed ID: 20442386 [TBL] [Abstract][Full Text] [Related]
23. Roscovitine is a proteostasis regulator that corrects the trafficking defect of F508del-CFTR by a CDK-independent mechanism. Norez C; Vandebrouck C; Bertrand J; Noel S; Durieu E; Oumata N; Galons H; Antigny F; Chatelier A; Bois P; Meijer L; Becq F Br J Pharmacol; 2014 Nov; 171(21):4831-49. PubMed ID: 25065395 [TBL] [Abstract][Full Text] [Related]
24. Antibiotic strategies for eradicating Pseudomonas aeruginosa in people with cystic fibrosis. Langton Hewer SC; Smyth AR Cochrane Database Syst Rev; 2014 Nov; (11):CD004197. PubMed ID: 25383937 [TBL] [Abstract][Full Text] [Related]
25. Tolerability and pharmacokinetic properties of ciprofloxacin dry powder for inhalation in patients with cystic fibrosis: a phase I, randomized, dose-escalation study. Stass H; Weimann B; Nagelschmitz J; Rolinck-Werninghaus C; Staab D Clin Ther; 2013 Oct; 35(10):1571-81. PubMed ID: 24054830 [TBL] [Abstract][Full Text] [Related]
26. Harnessing Neutrophil Survival Mechanisms during Chronic Infection by Marteyn BS; Burgel PR; Meijer L; Witko-Sarsat V Front Cell Infect Microbiol; 2017; 7():243. PubMed ID: 28713772 [TBL] [Abstract][Full Text] [Related]
27. An 8 week open-label interventional multicenter study to explore the lung clearance index as endpoint for clinical trials in cystic fibrosis patients ≥8 years of age, chronically infected with Pseudomonas aeruginosa. Sutharsan S; Naehrig S; Mellies U; Sieder C; Ziegler J BMC Pulm Med; 2020 Jun; 20(1):167. PubMed ID: 32532226 [TBL] [Abstract][Full Text] [Related]
28. Inhaled liposomal ciprofloxacin in patients with non-cystic fibrosis bronchiectasis and chronic lung infection with Pseudomonas aeruginosa (ORBIT-3 and ORBIT-4): two phase 3, randomised controlled trials. Haworth CS; Bilton D; Chalmers JD; Davis AM; Froehlich J; Gonda I; Thompson B; Wanner A; O'Donnell AE Lancet Respir Med; 2019 Mar; 7(3):213-226. PubMed ID: 30658914 [TBL] [Abstract][Full Text] [Related]
30. A phase 3, double-blind, parallel-group study to evaluate the efficacy and safety of tezacaftor in combination with ivacaftor in participants 6 through 11 years of age with cystic fibrosis homozygous for F508del or heterozygous for the F508del-CFTR mutation and a residual function mutation. Davies JC; Sermet-Gaudelus I; Naehrlich L; Harris RS; Campbell D; Ahluwalia N; Short C; Haseltine E; Panorchan P; Saunders C; Owen CA; Wainwright CE; J Cyst Fibros; 2021 Jan; 20(1):68-77. PubMed ID: 32967799 [TBL] [Abstract][Full Text] [Related]
33. Ivacaftor in subjects with cystic fibrosis who are homozygous for the F508del-CFTR mutation. Flume PA; Liou TG; Borowitz DS; Li H; Yen K; Ordoñez CL; Geller DE; Chest; 2012 Sep; 142(3):718-724. PubMed ID: 22383668 [TBL] [Abstract][Full Text] [Related]
34. Tezacaftor/Ivacaftor in Subjects with Cystic Fibrosis and F508del/F508del-CFTR or F508del/G551D-CFTR. Donaldson SH; Pilewski JM; Griese M; Cooke J; Viswanathan L; Tullis E; Davies JC; Lekstrom-Himes JA; Wang LT; Am J Respir Crit Care Med; 2018 Jan; 197(2):214-224. PubMed ID: 28930490 [TBL] [Abstract][Full Text] [Related]